REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters

Author:

Baum Alina1ORCID,Ajithdoss Dharani1ORCID,Copin Richard1,Zhou Anbo1,Lanza Kathryn1,Negron Nicole1,Ni Min1,Wei Yi1,Mohammadi Kusha1ORCID,Musser Bret1ORCID,Atwal Gurinder S.1,Oyejide Adelekan1ORCID,Goez-Gazi Yenny2,Dutton John2ORCID,Clemmons Elizabeth2ORCID,Staples Hilary M.2,Bartley Carmen2ORCID,Klaffke Benjamin2,Alfson Kendra2ORCID,Gazi Michal2,Gonzalez Olga2ORCID,Dick Edward2ORCID,Carrion Ricardo2ORCID,Pessaint Laurent3ORCID,Porto Maciel3,Cook Anthony3,Brown Renita3,Ali Vaneesha3ORCID,Greenhouse Jack3ORCID,Taylor Tammy3ORCID,Andersen Hanne3ORCID,Lewis Mark G.3ORCID,Stahl Neil1ORCID,Murphy Andrew J.1ORCID,Yancopoulos George D.1,Kyratsous Christos A.1ORCID

Affiliation:

1. Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591, USA.

2. Southwest National Primate Research Center, Texas Biomedical Research Institute, San Antonio, TX 78245, USA.

3. BIOQUAL, Rockville, MD 20850, USA.

Abstract

A beneficial cocktail Since the start of the coronavirus disease 2019 (COVID-19) pandemic, considerable effort has gone into generating and characterizing neutralizing antibodies that could be used as therapeutics. Studies in humanized mice and convalescent humans led to the development of a cocktail of two potent antibodies that simultaneously bind to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein and prevent the virus from entering host cells. Baum et al. evaluated the efficacy of this cocktail, REGN-COV2, in rhesus macaques, which may model mild disease, and in golden hamsters, which present more severe symptoms. The antibody cocktail provided benefits in both models when administered either prophylactically or therapeutically and is currently in clinical trials. Science , this issue p. 1110

Funder

Biomedical Advanced Research and Development Authority

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Cited by 452 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3